The Study of AZD8529 for Smoking Cessation in Female Smokers
Status: | Completed |
---|---|
Conditions: | Smoking Cessation, Tobacco Consumers |
Therapuetic Areas: | Pulmonary / Respiratory Diseases |
Healthy: | No |
Age Range: | 18 - 75 |
Updated: | 12/1/2017 |
Start Date: | July 2015 |
End Date: | January 2017 |
To evaluate the efficacy and safety of AZD8529 for smoking cessation in female smokers.
This is a 19-week, multi-center, randomized, Phase 2 clinical study comparing the efficacy of
two different doses of AZD8529 (1.5 and 40 mg) in smoking cessation. Up to 2 weeks will be
allowed for the Screening Period, followed by a 1-week, single-blind run-in period. At the
end of Study Week 1 (on Study Day 8), medication compliance will be one of the factors used
in a predictive enrichment strategy.
two different doses of AZD8529 (1.5 and 40 mg) in smoking cessation. Up to 2 weeks will be
allowed for the Screening Period, followed by a 1-week, single-blind run-in period. At the
end of Study Week 1 (on Study Day 8), medication compliance will be one of the factors used
in a predictive enrichment strategy.
Inclusion Criteria:
- Be a female smoker between the ages of 18 to 75 years.
- Want to quit smoking.
- Be currently (last 30 days) smoking 10 or more cigarettes per day and report less than
3 months of consecutive smoking abstinence during the past year.
- Be able, in the opinion of the site investigator (SI), to understand and follow all
protocol-specified instructions and understand and provide written informed consent.
- Be willing to provide personal information for entry into a clinical trial registry.
- Agree to use and continue using at least one acceptable contraceptive method (oral
contraceptives, IUDs, contraceptive implants under the skin, contraceptive rings or
patches or injections, diaphragms with spermicide, condoms with spermicide, or
abstinence) or, if not of childbearing potential, must fulfill one of the following
criteria at screening: post-menopausal defined as amenorrhea for at least 12 months
and with follicle stimulating hormone (FSH) levels in the laboratory defined
post-menopausal range and/or documentation of irreversible surgical sterilization by
hysterectomy, bilateral oophorectomy or bilateral salpingectomy or tubal ligation
verified by the Site Investigator.
- Agree not to use any other smoking behavioral intervention (self-help or formal
treatment), acupuncture, or other smoking cessation pharmacotherapy during the study.
- Agree to refrain from using dietary/herbal supplements other than vitamins and
minerals for 7 days prior to receiving study drug and throughout the 13-week treatment
period.
- Agree to attend all required clinic appointments (including 3 eye exams) during the
course of the 19-week study.
Exclusion Criteria:
- Please contact the site for more information
We found this trial at
9
sites
University of Cincinnati The University of Cincinnati offers students a balance of educational excellence and...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
630 W 168th St
New York, New York
New York, New York
212-305-2862
Phone: 646-774-6137
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials